CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company’s founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal’s Board of Directors. Succeeding her, David Soergel, M.D., has been appointed Executive Vice President, Chief Medical Officer, effective April 21, 2025.
After teaching Genetics and Medicine at the University of Pennsylvania, where she was one of the youngest women at that time to become a fully tenured Professor, Dr. Taub moved into senior R&D leadership roles at Bristol Myers Squibb and Roche. In 2011, she co-founded Madrigal with a vision to address unmet medical needs for patients with serious liver and cardiometabolic diseases. Under her leadership, the company achieved an unprecedented milestone 鈥� the development of the first FDA-approved medicine for the treatment of MASH, Rezdiffra鈩� (resmetirom).
“Becky’s visionary leadership and relentless commitment have been instrumental in Madrigal’s success and the success of the MASH field,” said Bill Sibold, Chief Executive Officer of Madrigal. “Her pioneering work as both a scientist and entrepreneur led to the development and approval of Rezdiffra 鈥� the first-ever FDA-approved medicine for MASH 鈥� bringing real hope to patients who previously had no options. We are incredibly grateful for her contributions and are fortunate to have her continued guidance as a strategic advisor and Madrigal board member. Becky represents the best of what our industry is capable of, and I hope her story will serve as an inspiration for people beginning their careers in biopharma.”
鈥淎s Becky moves into her new role, we鈥檙e thrilled to welcome David Soergel to Madrigal,鈥� said Sibold. 鈥淒ave brings more than 20 years of leadership experience in metabolic and cardiovascular disease drug development, spanning both biotech and large pharma. As we look to build a pipeline beyond Rezdiffra, Dave鈥檚 deep clinical development expertise and strong track record of advancing therapies across multiple therapeutic areas is exactly the kind of experience that aligns with where we鈥檙e taking the company.鈥�
鈥淚鈥檇 like to thank my colleagues, our research partners, and the many patients in the MASH community who have made invaluable contributions to Madrigal鈥檚 success,鈥� said Dr. Taub. 鈥淲hat started as a small team of fewer than 10 R&D professionals in Conshohocken, PA is now a commercial-stage biopharma company with more than five hundred employees across the U.S. and Europe. I look forward to supporting Dave in my role as a scientific and medical advisor as Madrigal enters its next phase.鈥�
Dr. Soergel joins Madrigal from Novartis, where he served as the Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. At Novartis, Dave led teams that designed and implemented evidence generation programs supporting the expansion of Entresto鈥檚 indications and uses. Additionally, he advanced novel medicines to approval for cardiovascular and renal diseases, including Leqvio, Fabhalta and Vanrafia, and served as the development lead for the acquisitions of the Medicines Company and Chinook Therapeutics. Prior to Novartis, Dr. Soergel held leadership roles at biotechnology companies, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, where he was responsible for the development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology, and heart failure and transplant at Johns Hopkins Hospital and the Children’s Hospital of Philadelphia.
鈥淚t is a great privilege to be succeeding Becky as Chief Medical Officer and I look forward to tapping into her expertise and guidance as I begin my new role at Madrigal,鈥� said Dr. Soergel. 鈥淚鈥檓 excited to be joining an R&D team that delivered the first approved therapy in a disease that has been a major challenge for drug development. With two fully enrolled outcomes studies of Rezdiffra underway, Madrigal is at the forefront of scientific innovation in MASH, and the company is well-positioned to build on its leadership position through pipeline expansion.鈥�
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal鈥檚 medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-尾 agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit聽.
